The successful clinical trials of mono (N)-substituted imidazole compounds such as miconazole and ketoconazole against infections with yeasts and filamentous fungi (5) have led to the development of newer compounds in which the imidazole ring is replaced by the related 1,2,4-triazole ring (2) . One such derivative, UK 49,858 [2-(2,4-difluorophenyl)l-,3-bis(lH-1,2,4-triazol-1-yl)-2-propanol], was synthesized by Pfizer Central Research, Sandwich, England (3) . Like ketoconazole, it is active when given orally and well tolerated by healthy human volunteers; doses of 1.4 mg/kg for 7 consecutive days and up to 0.7 mg/kg for 28 consecutive days have not shown any toxicity (Investigator's Reference Manual, Pfizer Inc., Groton, Conn., 1984). Orally administered UK 49,858 also appears to possess activity superior to that of ketoconazole in mice with lethal Candida albicans (6) and Aspergillus flavus (P. F. Troke, R. J. Andrews, M. S. Marriott, and K. Richardson (4) . Saccharomyces cerevisiae (HLR), originally obtained from Hoffman-LaRoche, Inc., Nutley, N.J., was used as a drug control organism for our susceptibility studies.
The number of cells for inocula was quantitated by hemacytometer counts, and the numbers of viable units were determined by colony counts on brain heart infusion agar (Difco Laboratories, Detroit, Mich.) supplemented with growth factor and cysteine as described in the procedure of Burt et al. (2) .
In vitro susceptibility studies. Antifungal susceptibility tests were conducted in 2% glucose-1% yeast extract broth or yeast nitrogen base broth (Difco Laboratories), supplemented with 1% dextrose, using procedures previously described (7) .
The MIC was the lowest concentration of drug that inhibited multiplication of the yeasts as determined by the absence of turbidity. Measurements were done when visible turbidity was noted in the control cultures (96 to 120 h).
Drug toxicity studies. Groups of 10 AKR and C57BL/6 mice were gavaged twice daily with 0.5-ml volumes of various concentrations of UK 49,858 dissolved in water for a total of 6 consecutive days. The concentrations of UK 49,858 used were serial twofold dilutions in water from 8.7 to 0.015 mg/ml. The range of daily doses for AKR mice was 414.3 to 0.7 mg/kg per day, and for C57BL/6 mice it was 483.3 to 0.9 mg/kg per day, for a total of 6 consecutive days. Deaths were recorded for up to 14 days after the final dose. Amphotericin B was administered by intraperitoneal (i.p.) injection on alternate days for a total of six injections according to procedures previously described (4 The LD50 values of amphotericin B for AKR and C57BL/6 mice were 23.8 + 3.5 and 21.4 ± 3.4 mg/kg per day, respectively. The maximum dose of amphotericin B which could be given i.p. without any deaths of AKR mice was 15.5 mg/kg per day; the equivalent dose in C57BL/6 mice was 13.9 mg/kg per day.
Experimental therapy. Untreated AKR mice injected with 5 x 106 viable cells (LD1oo) of H. capsulatum G217B were all dead by 7 days after infection. With this inoculum the PD50 was 6.2 ± 1.0 mg of UK 49,858 and 1.8 ± 0.6 mg of amphotericin B per kg. When an inoculum of 2LD1oo was used as the infecting dose, the PD50 was 47.6 ± 12.6 of UK 49,858 and 6.5 ± 1.6 mg of amphotericin B per kg. To achieve a similar LD100 for C57BL/6 mice, an inoculum of 2.5 x 106 viable cells of H. capsulatum G217B was-used. With this inoculum the PD50 was 9.2 ± 2.7 mg of UK 49,858 and 1.4 ± 0.9 mg of amphotericin 13 per kg per day. When 2LD10o was used as inoculum, the PD50 was 28.9 + 8.6 mg of UK 49,858 and 3.8 ± 1.5 mg of amphotericin B per kg per day.
The surviving AKR and C57BL/6 mice that received UK 49,858 or amphotericin B were not cured of their infections with viable H. capsulatum organisms cultured from spleens removed at necropsy from the survivors 4 weeks posttreatment. Exact quantitation of the spleens was difficult because of clumping and variations in spleen weights, but there did not appear to be differences between the two groups.
Therefore, despite its poor in vitro activity, UK 49,858 is an effective agent in vivo. This discrepancy between the in vitro and in vivo activity of this drug indicates the need for better and more relevant in vitro susceptibility testing.
Amphotericin B was 3.1 to 7.5 times more effective than UK 49,858 against this model of H. capsulatum infection in the two strains of mice. The difference between the 2 drugs depended on the strain of mouse and the infecting dose (Table 1) . When the maximally tolerated doses of the drugs were divided by the minimally effective doses to achieve 100% survival of the mice, the theraptutic/toxic ratios of each drug could be obtained. These values for UK 49,858 were 4.3 in AKR mice and 7.1 in C57BL/6; for amphotericin B they were 2 in both AKR and C57BL/6 mice. Therefore, it appears that UK 49,858 may be the more attractive agent in this infection, particularly because it achieved its therapeutic effects given orally.
UK 49,858 has been shown to have a broader spectrum of activity then ketoconazole (6) . For example, the doses of UK 49,858 that prevented death of 50% of mice given a lethal dose of Aspergillus flavus were 4-to 20-fold lower than ketoconazole doses in this model of infection (Troke et al. IXth Int. Cong. Int. Soc. Human Anim. Mycol., abstr. R2 -7, 1985) . In addition, UK 49,858 has been reported to be more active against murine candidiasis than ketoconazole (6), it can be administered both orally and intravenously, and it is excreted unchanged in the urine (S. Jevons and M. H. Tarbit, IXth Int. Cong. Int. Soc. Human Anim. Mycol., abstr. R2-3, 1985) . The latter property theoretically should make it useful in the treatment of fungal urinary tract infections. If its in vivo activity against other systemic fungal pathogens compares as favorably with amphotericin B as it does in the present study, UK 49,858 represents an exciting addition to antifungal therapy.
